Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)
March 26, 2019 9:28 AM EDTToday's Pre-Open Movers
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 66.8% HIGHER; announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of... More
Maxim Group Starts Biocept (BIOC) at Buy
March 26, 2019 7:37 AM EDTMaxim Group analyst Jason McCarthy initiates coverage on Biocept (NASDAQ: BIOC) with a Buy rating and a price target of $3.00.
We are initiating coverage of Biocept with a Buy rating and $3 price target. Biocepts Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates... More